{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:11:08Z","timestamp":1793725868112,"version":"4.6.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02667-8","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:59:07Z","timestamp":1780408747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting tumor-specific T cells with LAG3-directed interleukin-2 prevents T-cell exhaustion and reinvigorates antitumor immunity"],"prefix":"10.1038","volume":"11","author":[{"given":"Xiaohong","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaoyun","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8824-7668","authenticated-orcid":false,"given":"Zaopeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8441-6617","authenticated-orcid":false,"given":"Yang-Xin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"2667_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang, A. C. et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60\u201365 (2017).","journal-title":"Nature"},{"key":"2667_CR2","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184, 5309\u20135337 (2021).","journal-title":"Cell"},{"key":"2667_CR3","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","volume":"72","author":"SR Woo","year":"2012","unstructured":"Woo, S. R. et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72, 917\u2013927 (2012).","journal-title":"Cancer Res."},{"key":"2667_CR4","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1136\/gutjnl-2022-327133","volume":"72","author":"Z Tan","year":"2023","unstructured":"Tan, Z. et al. Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients. Gut 72, 1568\u20131580 (2023).","journal-title":"Gut"},{"key":"2667_CR5","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41590-022-01176-4","volume":"23","author":"C Guy","year":"2022","unstructured":"Guy, C. et al. LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation. Nat. Immunol. 23, 757\u2013767 (2022).","journal-title":"Nat. Immunol."},{"key":"2667_CR6","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1016\/j.cell.2024.07.016","volume":"187","author":"LP Andrews","year":"2024","unstructured":"Andrews, L. P. et al. LAG-3 and PD-1 synergize on CD8(+) T cells to drive T cell exhaustion and hinder autocrine IFN-\u03b3-dependent anti-tumor immunity. Cell 187, 4355\u20134372.e4322 (2024).","journal-title":"Cell"},{"key":"2667_CR7","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1158\/2326-6066.CIR-19-0146","volume":"7","author":"H Zelba","year":"2019","unstructured":"Zelba, H. et al. PD-1 and LAG-3 dominate checkpoint receptor-mediated T-cell inhibition in renal cell carcinoma. Cancer Immunol. Res. 7, 1891\u20131899 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"2667_CR8","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1016\/j.cell.2024.06.036","volume":"187","author":"AR Cillo","year":"2024","unstructured":"Cillo, A. R. et al. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8(+) T cells to promote antitumor immunity. Cell 187, 4373\u20134388.e4315 (2024).","journal-title":"Cell"},{"key":"2667_CR9","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1158\/1535-7163.MCT-18-1376","volume":"18","author":"E Burova","year":"2019","unstructured":"Burova, E. et al. Preclinical development of the anti-LAG-3 antibody REGN3767: characterization and activity in combination with the anti-PD-1 antibody cemiplimab in human PD-1xLAG-3-knockin mice. Mol. Cancer Ther. 18, 2051\u20132062 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"2667_CR10","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1038\/s41591-023-02593-0","volume":"29","author":"JJ Luke","year":"2023","unstructured":"Luke, J. J. et al. The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nat. Med. 29, 2814\u20132824 (2023).","journal-title":"Nat. Med."},{"key":"2667_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36979-y","volume":"14","author":"SY Lim","year":"2023","unstructured":"Lim, S. Y. et al. The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma. Nat. Commun. 14, 1516 (2023).","journal-title":"Nat. Commun."},{"key":"2667_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","volume":"22","author":"M Philip","year":"2022","unstructured":"Philip, M. & Schietinger, A. CD8(+) T cell differentiation and dysfunction in cancer. Nat. Rev. Immunol. 22, 209\u2013223 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"2667_CR13","doi-asserted-by":"publisher","first-page":"eaat1482","DOI":"10.1126\/sciimmunol.aat1482","volume":"3","author":"AK Abbas","year":"2018","unstructured":"Abbas, A. K., Trotta, E., R Simeonov, D., Marson, A. & Bluestone, J. A. Revisiting IL-2: Biology and therapeutic prospects. Sci. Immunol. 3, eaat1482 (2018).","journal-title":"Sci. Immunol."},{"key":"2667_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11782-w","volume":"10","author":"Z Sun","year":"2019","unstructured":"Sun, Z. et al. A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8(+) T-cell response and effective tumor control. Nat. Commun. 10, 3874 (2019).","journal-title":"Nat. Commun."},{"key":"2667_CR15","doi-asserted-by":"publisher","first-page":"111478","DOI":"10.1016\/j.celrep.2022.111478","volume":"41","author":"D VanDyke","year":"2022","unstructured":"VanDyke, D. et al. Engineered human cytokine\/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection. Cell Rep. 41, 111478 (2022).","journal-title":"Cell Rep."},{"key":"2667_CR16","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/s41551-021-00797-8","volume":"5","author":"B Zhang","year":"2021","unstructured":"Zhang, B. et al. Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells. Nat. Biomed. Eng. 5, 1288\u20131305 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"2667_CR17","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1158\/1078-0432.CCR-19-3354","volume":"26","author":"SN Quayle","year":"2020","unstructured":"Quayle, S. N. et al. CUE-101, a Novel E7-pHLA-IL2-Fc fusion protein, enhances tumor antigen-specific T-cell activation for the treatment of HPV16-driven malignancies. Clin. Cancer Res. 26, 1953\u20131964 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2667_CR18","doi-asserted-by":"publisher","first-page":"eaau3259","DOI":"10.1126\/scitranslmed.aau3259","volume":"11","author":"J Ishihara","year":"2019","unstructured":"Ishihara, J. et al. Targeted antibody and cytokine cancer immunotherapies through collagen affinity. Sci. Transl. Med. 11, eaau3259 (2019).","journal-title":"Sci. Transl. Med."},{"key":"2667_CR19","doi-asserted-by":"publisher","first-page":"1899469","DOI":"10.1080\/2162402X.2021.1899469","volume":"10","author":"SE Cha","year":"2021","unstructured":"Cha, S. E. et al. Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine. Oncoimmunology 10, 1899469 (2021).","journal-title":"Oncoimmunology"},{"key":"2667_CR20","doi-asserted-by":"publisher","first-page":"e153604","DOI":"10.1172\/JCI153604","volume":"132","author":"Z Ren","year":"2022","unstructured":"Ren, Z. et al. Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity. J. Clin. Invest. 132, e153604 (2022).","journal-title":"J. Clin. Invest."},{"key":"2667_CR21","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1016\/j.celrep.2018.07.043","volume":"24","author":"C Kudo-Saito","year":"2018","unstructured":"Kudo-Saito, C. et al. Blocking the FSTL1-DIP2A axis improves anti-tumor immunity. Cell Rep. 24, 1790\u20131801 (2018).","journal-title":"Cell Rep."},{"key":"2667_CR22","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1016\/j.celrep.2018.11.047","volume":"25","author":"KE Sivick","year":"2018","unstructured":"Sivick, K. E. et al. Magnitude of therapeutic STING activation determines CD8(+) T cell-mediated anti-tumor immunity. Cell Rep. 25, 3074\u20133085.e3075 (2018).","journal-title":"Cell Rep."},{"key":"2667_CR23","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1073\/pnas.88.11.4636","volume":"88","author":"K Sauv\u00e9","year":"1991","unstructured":"Sauv\u00e9, K. et al. Localization in human interleukin 2 of the binding site to the alpha chain (p55) of the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA 88, 4636\u20134640 (1991).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2667_CR24","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1016\/j.immuni.2023.11.005","volume":"56","author":"JC Beltra","year":"2023","unstructured":"Beltra, J. C. et al. Stat5 opposes the transcription factor Tox and rewires exhausted CD8(+) T cells toward durable effector-like states during chronic antigen exposure. Immunity 56, 2699\u20132718.e2611 (2023).","journal-title":"Immunity"},{"key":"2667_CR25","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi, M. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 26, 566\u2013576 (2020).","journal-title":"Nat. Med"},{"key":"2667_CR26","doi-asserted-by":"publisher","first-page":"6183","DOI":"10.1158\/0008-5472.CAN-21-0939","volume":"81","author":"T Oba","year":"2021","unstructured":"Oba, T., Kajihara, R., Yokoi, T., Repasky, E. A. & Ito, F. Neoadjuvant in situ immunomodulation enhances systemic antitumor immunity against highly metastatic tumors. Cancer Res. 81, 6183\u20136195 (2021).","journal-title":"Cancer Res."},{"key":"2667_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35431-x","volume":"14","author":"S Li","year":"2023","unstructured":"Li, S. et al. Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nat. Commun. 14, 8 (2023).","journal-title":"Nat. Commun."},{"key":"2667_CR28","doi-asserted-by":"publisher","first-page":"e1223002","DOI":"10.1080\/2162402X.2016.1223002","volume":"5","author":"VT Colluru","year":"2016","unstructured":"Colluru, V. T., Zahm, C. D. & McNeel, D. G. Mini-intronic plasmid vaccination elicits tolerant LAG3(+) CD8(+) T cells and inferior antitumor responses. Oncoimmunology 5, e1223002 (2016).","journal-title":"Oncoimmunology"},{"key":"2667_CR29","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1084\/jem.20160485","volume":"214","author":"JB Williams","year":"2017","unstructured":"Williams, J. B. et al. The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment. J. Exp. Med. 214, 381\u2013400 (2017).","journal-title":"J. Exp. Med"},{"key":"2667_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31504-z","volume":"13","author":"LL Niborski","year":"2022","unstructured":"Niborski, L. L. et al. CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas. Nat. Commun. 13, 3739 (2022).","journal-title":"Nat. Commun."},{"key":"2667_CR31","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41590-022-01384-y","volume":"24","author":"AA Saadey","year":"2023","unstructured":"Saadey, A. A. et al. Rebalancing TGF\u03b21\/BMP signals in exhausted T cells unlocks responsiveness to immune checkpoint blockade therapy. Nat. Immunol. 24, 280\u2013294 (2023).","journal-title":"Nat. Immunol."},{"key":"2667_CR32","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1172\/JCI31184","volume":"117","author":"JF Grosso","year":"2007","unstructured":"Grosso, J. F. et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J. Clin. Invest. 117, 3383\u20133392 (2007).","journal-title":"J. Clin. Invest"},{"key":"2667_CR33","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s41590-020-0760-z","volume":"21","author":"DT Utzschneider","year":"2020","unstructured":"Utzschneider, D. T. et al. Early precursor T cells establish and propagate T cell exhaustion in chronic infection. Nat. Immunol. 21, 1256\u20131266 (2020).","journal-title":"Nat. Immunol."},{"key":"2667_CR34","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.immuni.2019.09.013","volume":"51","author":"Z Chen","year":"2019","unstructured":"Chen, Z. et al. TCF-1-centered transcriptional network drives an effector versus exhausted CD8 T cell-fate decision. Immunity 51, 840\u2013855.e845 (2019).","journal-title":"Immunity"},{"key":"2667_CR35","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","volume":"571","author":"AC Scott","year":"2019","unstructured":"Scott, A. C. et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature 571, 270\u2013274 (2019).","journal-title":"Nature"},{"key":"2667_CR36","doi-asserted-by":"publisher","first-page":"eaba7918","DOI":"10.1126\/sciimmunol.aba7918","volume":"5","author":"T Sekine","year":"2020","unstructured":"Sekine, T. et al. TOX is expressed by exhausted and polyfunctional human effector memory CD8(+) T cells. Sci. Immunol. 5, eaba7918 (2020).","journal-title":"Sci. Immunol."},{"key":"2667_CR37","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-019-1326-9","volume":"571","author":"F Alfei","year":"2019","unstructured":"Alfei, F. et al. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature 571, 265\u2013269 (2019).","journal-title":"Nature"},{"key":"2667_CR38","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","volume":"571","author":"O Khan","year":"2019","unstructured":"Khan, O. et al. TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion. Nature 571, 211\u2013218 (2019).","journal-title":"Nature"},{"key":"2667_CR39","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1016\/j.molcel.2021.03.045","volume":"81","author":"Y Pritykin","year":"2021","unstructured":"Pritykin, Y. et al. A unified atlas of CD8 T cell dysfunctional states in cancer and infection. Mol. Cell 81, 2477\u20132493.e2410 (2021).","journal-title":"Mol. Cell"},{"key":"2667_CR40","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 8, 1069\u20131086 (2018).","journal-title":"Cancer Discov."},{"key":"2667_CR41","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41577-025-01161-6","volume":"9","author":"L Galluzzi","year":"2025","unstructured":"Galluzzi, L., Smith, K. N., Liston, A. & Garg, A. D. The diversity of CD8(+) T cell dysfunction in cancer and viral infection. Nat. Rev. Immunol. 9, 662\u2013679 (2025).","journal-title":"Nat. Rev. Immunol."},{"key":"2667_CR42","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998\u20131013.e1020 (2018).","journal-title":"Cell"},{"key":"2667_CR43","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.aaf0683","volume":"355","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst, A. O. et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science 355, 1423\u20131427 (2017).","journal-title":"Science"},{"key":"2667_CR44","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.aaf2807","volume":"354","author":"KE Pauken","year":"2016","unstructured":"Pauken, K. E. et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354, 1160\u20131165 (2016).","journal-title":"Science"},{"key":"2667_CR45","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/s41590-022-01338-4","volume":"23","author":"JR Giles","year":"2022","unstructured":"Giles, J. R. et al. Shared and distinct biological circuits in effector, memory and exhausted CD8(+) T cells revealed by temporal single-cell transcriptomics and epigenetics. Nat. Immunol. 23, 1600\u20131613 (2022).","journal-title":"Nat. Immunol."},{"key":"2667_CR46","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1016\/j.cell.2024.07.018","volume":"187","author":"SF Ngiow","year":"2024","unstructured":"Ngiow, S. F. et al. LAG-3 sustains TOX expression and regulates the CD94\/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity. Cell 187, 4336\u20134354.e4319 (2024).","journal-title":"Cell"},{"key":"2667_CR47","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1016\/j.cell.2025.02.014","volume":"188","author":"Y Jiang","year":"2025","unstructured":"Jiang, Y. et al. Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of signaling motifs. Cell 188, 2354\u20132371.e2318 (2025).","journal-title":"Cell"},{"key":"2667_CR48","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1038\/s44321-024-00098-y","volume":"16","author":"L Chocarro","year":"2024","unstructured":"Chocarro, L. et al. PD-1\/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets. EMBO Mol. Med. 16, 1791\u20131816 (2024).","journal-title":"EMBO Mol. Med"},{"key":"2667_CR49","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.immuni.2019.10.009","volume":"51","author":"R Zander","year":"2019","unstructured":"Zander, R. et al. CD4(+) T cell help is required for the formation of a cytolytic CD8(+) T cell subset that protects against chronic infection and cancer. Immunity 51, 1028\u20131042.e1024 (2019).","journal-title":"Immunity"},{"key":"2667_CR50","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","volume":"52","author":"JC Beltra","year":"2020","unstructured":"Beltra, J. C. et al. Developmental relationships of four exhausted CD8(+) T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity 52, 825\u2013841.e828 (2020).","journal-title":"Immunity"},{"key":"2667_CR51","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.immuni.2019.11.002","volume":"51","author":"WH Hudson","year":"2019","unstructured":"Hudson, W. H. et al. Proliferating transitory T cells with an effector-like transcriptional signature emerge from PD-1(+) Stem-like CD8(+) T cells during chronic infection. Immunity 51, 1043\u20131058.e1044 (2019).","journal-title":"Immunity"},{"key":"2667_CR52","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","volume":"38","author":"F Dammeijer","year":"2020","unstructured":"Dammeijer, F. et al. The PD-1\/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes. Cancer Cell 38, 685\u2013700.e688 (2020).","journal-title":"Cancer Cell"},{"key":"2667_CR53","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1016\/j.cell.2022.09.020","volume":"185","author":"Q Huang","year":"2022","unstructured":"Huang, Q. et al. The primordial differentiation of tumor-specific memory CD8(+) T cells as bona fide responders to PD-1\/PD-L1 blockade in draining lymph nodes. Cell 185, 4049\u20134066.e4025 (2022).","journal-title":"Cell"},{"key":"2667_CR54","doi-asserted-by":"publisher","first-page":"e000867","DOI":"10.1136\/jitc-2020-000867","volume":"8","author":"ZS Buchwald","year":"2020","unstructured":"Buchwald, Z. S. et al. Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy. J. Immunother. Cancer 8, e000867 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"2667_CR55","doi-asserted-by":"publisher","first-page":"e124507","DOI":"10.1172\/jci.insight.124507","volume":"3","author":"MF Fransen","year":"2018","unstructured":"Fransen, M. F. et al. Tumor-draining lymph nodes are pivotal in PD-1\/PD-L1 checkpoint therapy. JCI Insight 3, e124507 (2018).","journal-title":"JCI Insight"},{"key":"2667_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37825-x","volume":"14","author":"K Onyshchenko","year":"2023","unstructured":"Onyshchenko, K. et al. Expansion of circulating stem-like CD8(+) T cells by adding CD122-directed IL-2 complexes to radiation and anti-PD1 therapies in mice. Nat. Commun. 14, 2087 (2023).","journal-title":"Nat. Commun."},{"key":"2667_CR57","doi-asserted-by":"publisher","first-page":"e171154","DOI":"10.1172\/JCI171154","volume":"134","author":"E Frijlink","year":"2024","unstructured":"Frijlink, E. et al. PD-1 or CTLA-4 blockade promotes CD86-driven Treg responses upon radiotherapy of lymphocyte-depleted cancer in mice. J. Clin. Invest. 134, e171154 (2024).","journal-title":"J. Clin. Invest."},{"key":"2667_CR58","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-023-01462-z","volume":"8","author":"S Guo","year":"2023","unstructured":"Guo, S. et al. Radiation-induced tumor immune microenvironments and potential targets for combination therapy. Signal Transduct. Target Ther. 8, 205 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2667_CR59","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/nrc3186","volume":"12","author":"MA Swartz","year":"2012","unstructured":"Swartz, M. A. & Lund, A. W. Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity. Nat. Rev. Cancer 12, 210\u2013219 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"2667_CR60","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ccr.2012.01.008","volume":"21","author":"JJ Engelhardt","year":"2012","unstructured":"Engelhardt, J. J. et al. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell 21, 402\u2013417 (2012).","journal-title":"Cancer Cell"},{"key":"2667_CR61","doi-asserted-by":"publisher","first-page":"4616","DOI":"10.3390\/cancers13184616","volume":"13","author":"Y Kanda","year":"2021","unstructured":"Kanda, Y., Okazaki, T. & Katakai, T. Motility dynamics of T cells in tumor-draining lymph nodes: a rational indicator of antitumor response and immune checkpoint blockade. Cancers (Basel) 13, 4616 (2021).","journal-title":"Cancers (Basel)"},{"key":"2667_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0397-0","volume":"13","author":"MM van den Heuvel","year":"2015","unstructured":"van den Heuvel, M. M. et al. NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy. J. Transl. Med. 13, 32 (2015).","journal-title":"J. Transl. Med."},{"key":"2667_CR63","doi-asserted-by":"publisher","first-page":"1913791","DOI":"10.1080\/19420862.2021.1913791","volume":"13","author":"I Waldhauer","year":"2021","unstructured":"Waldhauer, I. et al. Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy. MAbs 13, 1913791 (2021).","journal-title":"MAbs"},{"key":"2667_CR64","doi-asserted-by":"publisher","first-page":"5063","DOI":"10.1158\/0008-5472.CAN-20-0002","volume":"80","author":"JM Drerup","year":"2020","unstructured":"Drerup, J. M. et al. CD122-selective IL2 complexes reduce immunosuppression, promote Treg fragility, and sensitize tumor response to PD-L1 blockade. Cancer Res. 80, 5063\u20135075 (2020).","journal-title":"Cancer Res"},{"key":"2667_CR65","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41586-022-05257-0","volume":"610","author":"M Hashimoto","year":"2022","unstructured":"Hashimoto, M. et al. PD-1 combination therapy with IL-2 modifies CD8(+) T cell exhaustion program. Nature 610, 173\u2013181 (2022).","journal-title":"Nature"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02667-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02667-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02667-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:22:17Z","timestamp":1780410137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02667-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2667"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02667-8","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"207"}}